Bain Capital Life Sciences
Dedicated life sciences fund within Bain Capital, one of the world's leading private investment firms. Combines deep scientific expertise with operational support and access to Bain Capital's global resources.
Location
Boston, USA
Founded
2016
AUM
$5B+
Investment Range
$25M - $200M
Focus
biotech-focused
Fund Stages
series-a, series-b, series-c, growth
Investment Thesis
Bain Capital Life Sciences invests across the spectrum of life sciences, from therapeutics to diagnostics, devices, and services. They focus on companies with transformative potential, providing not just capital but operational expertise, strategic guidance, and access to Bain Capital's global network and resources.
Team
Partners / Managing Directors (Health & Bio Focus)
- Adam Koppel, MD, PhD - Managing Director
- Jeffrey Schwartz - Managing Director
- Andrew Hack, MD, PhD - Partner
- Sheryl Katz, MD - Partner
Other Key Team Members
- Joshua Bekenstein - Bain Capital Co-Chairman
- John Connaughton - Bain Capital Co-Chairman
Focus Areas
- Therapeutics
- Oncology
- Rare Diseases
- Medical Devices
- Diagnostics
- Healthcare Services
- Biopharma Services
Notable Exits
- Cerevel Therapeutics - IPO (2020, NASDAQ: CERE)
- Springworks Therapeutics - IPO (2019, NASDAQ: SWTX)
- EQRx - Continues growth in oncology
- Neumora Therapeutics - IPO (2023, NASDAQ: NMRA)